pharmadog

Jobs

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

News

when

Latest
Archive

by source

All Sources
Sources Page

Companies

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

Calendar

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

made by humans and a good dog

home
jobs
news
cal
search

Betapace · pharmadog

pharmadog
drugs
Betapace

drug

patient view →

save

sotalol hydrochloride

Marketedupdated 2mo ago

by Covis Pharmaceuticals Inc (Inactive)

Approved

community read0 votes

indications

investigational

Atrial Fibrillation

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Betapace

generic

sotalol hydrochloride

indication

Atrial Fibrillation

phase

marketed

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Data sources

ClinicalTrials.gov

last refreshed 51m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Patent cliff

source: FDA Orange Book

first barrier falls

Aug 14, 2028

~2.1 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (11)

Aug 21, 2039method-of-use (U-3549)US 11583216
Apr 5, 2039method-of-use (U-3125)US 10799138
Aug 14, 2038method-of-use (U-3547)US 10512620
Aug 14, 2038method-of-use (U-2769)US 11696902
Aug 14, 2038method-of-use (U-2769)US 12390431
Aug 31, 2035formulationUS 9724297
Nov 19, 2034method-of-use (U-2494)US 11850222
Apr 1, 2034formulationUS 10206895
Apr 1, 2034formulationUS 11013703
Apr 1, 2034method-of-use (U-2494)US 12290495
Aug 14, 2028method-of-use (U-2769)US 124031092.1y